DUPIXENT specifically targets a source of underlying inflammation in AD1


IL-4 and IL-13 are important in the development of Type 2 inflammation and its downstream effects1

DUPIXENT is a fully human monoclonal antibody for administration by subcutaneous injecton1

Learn more about how DUPIXENT works

  • DUPIXENT specifically targets IL-4 receptor, inhibiting IL-4/ IL-13 signalling1–4


    Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131-4

    Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41

    Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131

  • DUPIXENT specifically targets IL-4 receptor, inhibiting IL-4/ IL-13 signalling1–4


    Binds specifically to the IL-4Rα subunit shared by the receptor complexes for IL-4 and IL-131-4

    Selectively inhibits the signalling of IL-4 via the Type 1 and 2 receptors for IL-41

    Selectively inhibits IL-13 signalling via the Type 2 receptor for IL-131

DUPIXENT is a targeted immunomodulator unlike broad spectrum immunosuppressants1


Overview of AD

Find out more about how AD has a continuous inflamation cycle.




Find out more


Request a representative call

Have a question about DUPIXENT?
Get answers from a representative.




Find out more


Inflammatory pathways

What are the main inflammatory pathways involved in the disease? Find out about the pathway involved in AD.



Find out more

    AD, atopic dermatitis; γC, gamma C subunit; IL, interleukin; IL-4Rα; Interleukin 4 receptor alpha;  IL-13Rα1, interleukin 13 receptor alpha 1;  ILC,  innate lymphoid cells;  JAK, Janus kinase; 
    Th,
    T-helper cells;  TYK2, tyrosine kinase 2.

    References

    1. DUPIXENT Summary of Product Characteristics. September 2021.
    2. Guttman-Yassky E, et al. J Allergy Clin Immunol. 2019;143:155–172.
    3. Gandhi NA, et al. Nat Rev Drug Discov. 2016;15:35–50.
    4. D’Erme A, et al. Drug Des Devel Ther. 2017;11:1473–1480.
    5. McCormick M, et al. Cytokine. 2015;75(1):38–50.

MAT-IE-2101040(v4.0) | Date of preparation: February 2022